This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Eugenie S. Kleinerman, holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.
Richard Gorlick, is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Bookmonger.Ltd, HILLSIDE, NJ, Etats-Unis
hardcover. Etat : Very Good. Crease on cover*. N° de réf. du vendeur mon0000651347
Quantité disponible : 1 disponible(s)
Vendeur : Universitätsbuchhandlung Herta Hold GmbH, Berlin, Allemagne
2nd ed. 2020. 18 x 25 cm. XIII, 212 S. XIII, 212 p. 24 illus., 17 illus. in color. (Advances in Experimental Medicine and Biology). Sprache: Englisch. N° de réf. du vendeur 1945VB
Quantité disponible : 1 disponible(s)
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur e9e5f105b74711f2746039373fa6c58d
Quantité disponible : Plus de 20 disponibles
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783030430313_new
Quantité disponible : Plus de 20 disponibles
Vendeur : moluna, Greven, Allemagne
Gebunden. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Thoroughly updated and revised, the second edition is a comprehensive and in-depth look at new developments in a rapidly developing fieldEdited by two internationally recognized, leading experts on osteosarcoma and sarcoma, the second editi. N° de réf. du vendeur 448681993
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes,Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, area timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma. 228 pp. Englisch. N° de réf. du vendeur 9783030430313
Quantité disponible : 2 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. N° de réf. du vendeur 26376878618
Quantité disponible : 4 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand. N° de réf. du vendeur 369166789
Quantité disponible : 4 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 228 pp. Englisch. N° de réf. du vendeur 9783030430313
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes,Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, area timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma. N° de réf. du vendeur 9783030430313
Quantité disponible : 1 disponible(s)